programmed cell death 1 ligand 1

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
programmed cell death 1 ligand 1 (Human)

GtoPdb Ligand ID: 9606

Abbreviated name: PD-L1

Synonyms: B7 homolog 1 | B7-H1 | PDL1 | programmed death ligand 1

Compound class: Endogenous peptide in human, mouse or rat

Comment: This is one of the ligands for the PD-1 receptor. It is a single-pass type I membrane protein. The PD-L1/PD-1 interaction is an established immune checkpoint. Both the ligand and receptor are targets for novel immuno-oncology therapeutics, as over-expression of either of these proteins is a mechanism used by tumour cells to evade immune detection and destruction. Already the target of approved immunotherapeutics in the form of monoclonal antibodies, small molecules targeting the PD-1/PD-L1 checkpoint are now in development to address the shortcomings associated with the current antibody therapies (including, poor susceptibility rate to single immune checkpoint pathway inhibitors, long half-life of antibodies and association with the development of adverse events, problems connected to the requirement for intravenous infusions) [9,20].

Species: Human

No information available.

No information available.

Summary of Clinical Use
PD-L1 is an important immunopharmacological drug discovery target, as many types of cancer cells express this ligand [7,11,25] as a means of evading immune detection and destruction by T-cell-mediated responses. Three monoclonal antibodies directed against PD-L1 are approved cancer therapeutics. Combined anti-PD-L1+anti-CTLA-4 therapy has shown benefits over anti-PD-L1 monotherapy in head and neck cancer. Compared to monotherapy, the combination approach is reported to induce more efficient CD4⁺ T cell trafficking from lymph nodes to tumours and to promote expansion toward T helper 1 phenotype [4].Additional reading: [15] and [13].

Summary of Clinical Use

PD-L1 is an important immunopharmacological drug discovery target, as many types of cancer cells express this ligand [7,11,25] as a means of evading immune detection and destruction by T-cell-mediated responses. Three monoclonal antibodies directed against PD-L1 are approved cancer therapeutics. Combined anti-PD-L1+anti-CTLA-4 therapy has shown benefits over anti-PD-L1 monotherapy in head and neck cancer. Compared to monotherapy, the combination approach is reported to induce more efficient CD4⁺ T cell trafficking from lymph nodes to tumours and to promote expansion toward T helper 1 phenotype [4].Additional reading: [15] and [13].